Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.
I. Karaiskos,L. Friberg,5 作者,H. Giamarellou
2016 · DOI: 10.1016/j.ijantimicag.2016.06.008
International Journal of Antimicrobial Agents · 引用数 36
TLDR
Following implementation of a predicted pharmacokinetic model on plasma CMS/colistin concentrations, a LD of 12 MU CMS appears more appropriate, whilst a CMS maintenance dosage of at least 6.5-7.5 MU q12h is suggested in patients undergoing CVVHDF, however, further clinical studies are warranted to assess the safety.